(NEW YORK))–Freedom Leaf, Inc. (OTCQB: FRLF) stock has been rallying on news that Paul Pelosi Jr. has been appointed the new Chairman of Freedom Leaf’s Board of Directors.
Register to our free investor mailing list to get the latest news and alerts on todays fastest running stocks.
Mr. Paul Pelosi Jr. is the son of U.S. House Minority Leader Nancy Pelosi, and has an extensive career advising companies on corporate governance, sustainability, and public policy. Mr. Pelosi graduated Cum Laude from Georgetown University with a Bachelor of Arts, and holds an MBA with an emphasis in International Business. Previously, Mr. Pelosi has served as the President of the SF Commission on the Environment and was the founding member of Cisco Systems Connected Urban Development team.
Mr. Pelosi is currently Executive Director of the Corporate Governance Initiative (CGI), an organization that is committed to assisting companies adhere to a system of guidelines, practices, and procedures by which a company is directed and controlled. The Corporate Governance Initiative also helps companies create policies to find better balance between the interests of a company’s many stakeholders, such as shareholders, management, patrons, providers, investors, government and the public.
Prior to CGI, Mr. Pelosi has served organizations at the executive and leadership levels, and has a wide scope of prospective and understanding when it comes to business. Mr. Pelosi has experience advising both emerging start-ups and Fortune 500 companies, including Bank of America, JP Morgan, Airpatrol Corporation, and the NASA Ames Research Center.
This news has caught the attention of traders as the stock has shown a sharp increase in both volume and price over the past few sessions. Ludlow Research, who recently had a ‘speculative’ target on FRLF of around $0.10 per share, updated their opinion in a note to their subscribers that the appointment of Mr. Pelosi could be a real game changer for the Company.
They stated that not only does this bring FRLF a real lift of credibility, along with the well pool of contacts Mr. Pelosi might be able to bring to the table, but this may also set up Freedom Leaf to become a major lobbying force on both the State and Federal level in regards to legalization of marijuana and hemp in the United States, and Internationally.
Combining their media leverage with their magazine growth, high standard of board governance and compliance, and the potential for sharp increase in revenues from their Hempology division, this story may only just be beginning.
For this reason Ludlow Research said they were increasing their short term valuation opinion on FRLF from $0.10 to now $0.25 per share based on these new developments.
IDVV Management Change
Another cannabis play being highlighted by Ludlow Research is International Endeavors Corp. (OTCMKTS:IDVV) who also just announced the appointment of a high caliber executive as their new CEO.
The Company just recently appointed Mr. Steve Kubby as their new acting CEO for IDVV. Mr. Kubby played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc. (OTCMKTS: CBDS), and has authored 2 books on drug policy reform. Mr. Kubby’s distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.
Kubby Cryogenics manufacturing division produces a unique biomedicine from the raw cannabis plant. This new class of medicine is the company’s own proprietary method capturing the vitality of the raw plant in its extraction process.
This small batch, apothecary approach captures the live resins that have medical benefits for a number of ailments, including: cancer, inflammatory disease, epilepsy, brain injury, autism, Alzheimer’s.
Ludlow Research stated that based on these major management additions these two cannabis plays offer real upside potential within this sector based on these individuals past experience, and what they may bring to the table in developing these two companies going forward.
About Freedom Leaf
Freedom Leaf, Inc., The Marijuana Legalization Company™, is a fully reporting and audited, publicly traded company trading under the symbol (OTCQB: FRLF). Freedom Leaf, Inc. is a leading go-to resource in the cannabis, medical marijuana, and industrial hemp industry. It is involved in mergers and acquisitions and business consulting in the marijuana industry, including incubation/acceleration and spin offs of new marijuana/hemp related companies.
Freedom Leaf, Inc.’s flagship publication is Freedom Leaf Magazine, “The Good News in Marijuana Reform”. The company produces a portfolio of news, print and digital multi-media verticals, websites, blogs and web advertising, for the ever-changing emerging cannabis, medical marijuana and industrial hemp industry. www.FreedomLeafInc.com
Freedom Leaf, Inc. does not handle, grow, sell, or dispense marijuana. All of our European activities are in full compliance with relevant EU laws.
About International Endeavors Corporation
International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com
Sign up to our free investor mailing list for updates on new research alerts, news updates, and investor opportunities